Better Nuclear Energy Stock: Oklo Vs. Centrus Energy

Why It Matters

The partnership accelerates a domestic HALEU supply chain essential for the U.S. nuclear expansion, and Centrus’s near‑term revenue stream makes it a more compelling investment relative to Oklo’s longer‑term rollout.

Key Takeaways

• Joint venture targets HALEU de‑conversion and fuel‑cycle tech.
• Oklo’s Aurora reactors rely on Meta‑funded 1.2 GW Ohio campus.
• Centrus holds sole NRC‑approved HALEU enrichment license in U.S.
• $900 million DOE order will bring Piketon cascade online 3.5 years.
• Centrus profitable now; Oklo not until post‑2027, weaker buy.

Pulse Analysis

The United States is rapidly reshaping its nuclear strategy, with policymakers emphasizing domestic HALEU production to reduce reliance on foreign fuel sources. By combining Oklo’s advanced reactor designs with Centrus’s enrichment capabilities, the joint venture aims to close a critical gap in the high‑assay fuel supply chain, positioning both firms to benefit from forthcoming federal incentives and licensing frameworks. This collaboration also signals broader industry confidence that next‑generation reactors will soon move from pilot projects to commercial deployment.

Oklo’s Aurora powerhouses leverage liquid‑metal‑cooled sodium fast‑reactor technology, a heritage of the historic EBR‑II experiment. The partnership with Meta Platforms provides upfront capital through prepaid power agreements, allowing Oklo to fund the Ohio campus while de‑risking construction costs. However, the company faces a protracted timeline: the first unit is not expected to operate until late 2027, and profitability remains distant. Investors must weigh the technological promise against the inherent uncertainties of scaling novel reactor designs and securing a reliable HALEU supply.

Centrus Energy enjoys a unique market position as the sole NRC‑approved HALEU producer, giving it a first‑mover advantage in a nascent but strategically vital segment. The $900 million Department of Energy contract to expand the Piketon facility underscores federal commitment to domestic enrichment and accelerates the plant’s operational readiness to roughly 2028. Coupled with its existing profitable LEU business, Centrus offers a clearer path to cash flow and dividend potential. For investors seeking exposure to the nuclear renaissance with nearer‑term upside, Centrus presents a more compelling risk‑adjusted profile than Oklo’s longer‑term play.